2015
DOI: 10.22270/jddt.v5i1.995
|View full text |Cite
|
Sign up to set email alerts
|

Nanosuspension Technology: A Innovative Slant for Drug Delivery System and Permeability Enhancer for Poorly Water Soluble Drugs

Abstract: Nanosuspension contains submicron colloidal dispersion of pharmaceutical active ingredient particles in a liquid phase stabilized by surfactants. The poor water solubility of drugs is major problem for drug formulation. The reduction of drug particles into the sub-micron range leads to a significant increase in the dissolution rate, bioavailability as well as improve stability. Nanosuspension consists of the pure poorly water-soluble drug without any matrix material suspended in dispersion. Nanosuspension many… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(15 citation statements)
references
References 46 publications
(104 reference statements)
0
15
0
Order By: Relevance
“…However, the development of mechanical attrition processes [64] (for example nanomilling technologies and high pressure homogenisation) and non-attrition nanoparticle fabrication (for example emulsion-templated freeze drying) has allowed access to nano-scale solid drug particles (< 1 μm) [65-68]. The rilpivirine LA and cabotegravir LA options [6, 7] that are in extended clinical trials (including evaluation of simultaneous combination in LATTE 2) are based upon this technology.…”
Section: Emerging Technologies For La Formulationmentioning
confidence: 99%
“…However, the development of mechanical attrition processes [64] (for example nanomilling technologies and high pressure homogenisation) and non-attrition nanoparticle fabrication (for example emulsion-templated freeze drying) has allowed access to nano-scale solid drug particles (< 1 μm) [65-68]. The rilpivirine LA and cabotegravir LA options [6, 7] that are in extended clinical trials (including evaluation of simultaneous combination in LATTE 2) are based upon this technology.…”
Section: Emerging Technologies For La Formulationmentioning
confidence: 99%
“…Nonvolatile solvent present in the liquisolid system facilitates wetting of drug particles by decreasing interfacial tension between dissolution medium and tablet surface. Shah [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] Classification based on type of liquid medication contain there in:…”
Section: Liquisolid Methodmentioning
confidence: 99%
“…Limitation regarding this method is at high temperature many drug may get degraded. [30][31][32][33][34][35][36][37][38] : HME can be simply defined as the process of forming a new material (the extrude) by forcing it through an orifice or die under controlled conditions, such as temperature, mixing, feed-rate and pressure. HME differs from simple extrusion in that, polymer, drug and excipients blends are mixed thoroughly in the molten state in this process, needing no solvents for granulation.…”
Section: Difficulty In Incorporating Into Formulation Of Dosage Formsmentioning
confidence: 99%
“…Various formulation parameters that play a crucial role in the successful formulation of drugs are aqueous solubility, stability at ambient temperature and humidity, photo stability, compatibility with solvent and excipients 9 .…”
Section: Issn: 2250-1177 [50] Coden (Usa): Jddtaomentioning
confidence: 99%